Ana Lako

6.1k total citations
17 papers, 573 citations indexed

About

Ana Lako is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Ana Lako has authored 17 papers receiving a total of 573 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 8 papers in Immunology and 7 papers in Molecular Biology. Recurrent topics in Ana Lako's work include Cancer Immunotherapy and Biomarkers (12 papers), Immunotherapy and Immune Responses (7 papers) and Cancer Genomics and Diagnostics (3 papers). Ana Lako is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Immunotherapy and Immune Responses (7 papers) and Cancer Genomics and Diagnostics (3 papers). Ana Lako collaborates with scholars based in United States, Spain and Germany. Ana Lako's co-authors include Scott J. Rodig, Mikel Lipschitz, Margaret A. Shipp, Gabriel K. Griffin, Pei-Hsuan Chen, Evisa Gjini, F. Stephen Hodi, Yubao Wang, Jean J. Zhao and Timothy J. Mitchison and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Ana Lako

17 papers receiving 569 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ana Lako United States 10 266 258 171 136 120 17 573
Camille Franchet France 12 200 0.8× 246 1.0× 148 0.9× 102 0.8× 108 0.9× 33 529
Sangok Kim South Korea 9 390 1.5× 153 0.6× 111 0.6× 175 1.3× 211 1.8× 15 652
Qingqing Ding United States 10 406 1.5× 350 1.4× 108 0.6× 77 0.6× 106 0.9× 34 732
Neha Luthar United States 6 236 0.9× 292 1.1× 124 0.7× 49 0.4× 64 0.5× 6 525
Anna Schmitt Germany 13 451 1.7× 418 1.6× 90 0.5× 167 1.2× 195 1.6× 22 828
Torill Høiby Norway 6 318 1.2× 255 1.0× 269 1.6× 45 0.3× 100 0.8× 8 658
Octavio A. Romero Spain 12 575 2.2× 208 0.8× 100 0.6× 230 1.7× 125 1.0× 15 721
Melinda S. Gordon United States 10 394 1.5× 195 0.8× 155 0.9× 74 0.5× 251 2.1× 25 683
Antonios Papanicolau‐Sengos United States 12 237 0.9× 275 1.1× 158 0.9× 54 0.4× 165 1.4× 36 563
Barbara Martinoglio Italy 4 171 0.6× 185 0.7× 51 0.3× 158 1.2× 98 0.8× 5 396

Countries citing papers authored by Ana Lako

Since Specialization
Citations

This map shows the geographic impact of Ana Lako's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana Lako with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana Lako more than expected).

Fields of papers citing papers by Ana Lako

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ana Lako. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana Lako. The network helps show where Ana Lako may publish in the future.

Co-authorship network of co-authors of Ana Lako

This figure shows the co-authorship network connecting the top 25 collaborators of Ana Lako. A scholar is included among the top collaborators of Ana Lako based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ana Lako. Ana Lako is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Hodi, F. Stephen, Anita Giobbie‐Hurder, Kwasi Adu‐Berchie, et al.. (2025). First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma. Cancer Immunology Research. 13(7). 978–989. 5 indexed citations
2.
Saad, Fred, Teresa Alonso‐Gordoa, Philippe Barthélémy, et al.. (2025). Circulating tumor DNA levels and related kinetics as prognostic biomarkers for clinical outcomes in mCRPC: A post hoc analysis of CM 7DX.. Journal of Clinical Oncology. 43(5_suppl). 252–252. 1 indexed citations
3.
Garman, Bradley, Can Jiang, Sherif Daouti, et al.. (2023). Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands. Frontiers in Immunology. 14. 1151748–1151748. 9 indexed citations
4.
Shah, Hina, Yating Wang, Su–Chun Cheng, et al.. (2022). Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers. JAMA Otolaryngology–Head & Neck Surgery. 148(3). 268–268. 9 indexed citations
5.
Boucher, Yves, Ashwin S. Kumar, Jessica M. Posada, et al.. (2021). Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients. npj Precision Oncology. 5(1). 62–62. 30 indexed citations
6.
Font‐Tello, Alba, Nikolas Kesten, Yingtian Xie, et al.. (2020). FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues. Nature Protocols. 15(8). 2503–2518. 22 indexed citations
7.
Miller, Brian C., Debattama R. Sen, Rose Al Abosy, et al.. (2020). Abstract A83: Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Cancer Immunology Research. 8(3_Supplement). A83–A83. 1 indexed citations
8.
Aktürk, Güray, Edwin R. Parra, Ana Lako, et al.. (2020). CIMAC-CIDC tissue imaging harmonization.. Journal of Clinical Oncology. 38(15_suppl). 3125–3125. 1 indexed citations
9.
Monjazeb, Arta M., Anita Giobbie‐Hurder, Ana Lako, et al.. (2019). Analysis of colorectal cancer patients treated on ETCTN 10021: A multicenter randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation.. Journal of Clinical Oncology. 37(8_suppl). 49–49. 9 indexed citations
10.
Miller, Brian C., Debattama R. Sen, Rose Al Abosy, et al.. (2019). Abstract 2701: Functionally specialized subsets of exhausted CD8+ T cells mediate tumor control and differentially respond to checkpoint blockade. Cancer Research. 79(13_Supplement). 2701–2701. 3 indexed citations
11.
Chapuy, Bjoern, Chip Stewart, Andrew Dunford, et al.. (2019). Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. Blood. 134(26). 2369–2382. 62 indexed citations
12.
Patel, Sanjay S., Jason L. Weirather, Mikel Lipschitz, et al.. (2019). The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4- positive T-cells that are PD-1-negative. Blood. 134(23). 2059–2069. 82 indexed citations
13.
Moreira, Raphael Brandão, Lana Hamieh, Evisa Gjini, et al.. (2017). Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab. Journal for ImmunoTherapy of Cancer. 5(1). 61–61. 2 indexed citations
14.
Wu, Xinqi, Anita Giobbie‐Hurder, Xiaoyun Liao, et al.. (2016). Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. Cancer Immunology Research. 5(1). 17–28. 123 indexed citations
15.
Norberg, Erik, Ana Lako, Pei-Hsuan Chen, et al.. (2016). Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets. Cell Death and Differentiation. 24(2). 251–262. 61 indexed citations
16.
Wang, Yubao, Michael J. Begley, Qing Li, et al.. (2016). Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival. Proceedings of the National Academy of Sciences. 113(35). 9810–9815. 58 indexed citations
17.
Wang, Yubao, Youngmi Lee, Lukas Baitsch, et al.. (2014). MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. eLife. 3. e01763–e01763. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Camille Franchet Breakdown of academic impact, for papers by Sangok Kim Breakdown of academic impact, for papers by Qingqing Ding Breakdown of academic impact, for papers by Neha Luthar Breakdown of academic impact, for papers by Anna Schmitt Breakdown of academic impact, for papers by Torill Høiby Breakdown of academic impact, for papers by Octavio A. Romero Breakdown of academic impact, for papers by Melinda S. Gordon Breakdown of academic impact, for papers by Antonios Papanicolau‐Sengos Breakdown of academic impact, for papers by Barbara Martinoglio
Rankless by CCL
2026